The Smoking cessation Aids Market is predicted to witness growing during the forecast period. Smoking is one in every of the key causes of lung cancer and different respiratory and viscus diseases. Awareness regarding these health hazards has influenced the people to adopt smoking stop medical aid. the attention among the people is thru digital media, medium and different sources of knowledge has established to be effective in curbing nicotine addiction crisis to some extent.
Cigarette smoking remains the leading reason for preventable disease, disability, and death. in step with Centers for malady control and hindrance (CDC), In 2023, nearly 14 of each 100 U.S. adults aged eighteen years or older (14.0%) preserved cigarettes. This hints at a high usage of de-addiction product. Also, this depicts the growing awareness of the individuals and their readiness to quit smoking. There are non-government and government institutions operating to coach and facilitate individuals quit smoking that's engaged dedicatedly, to bring the quantity of smokers down. as an example, in 2017, the U.S. Food associate degreed Drug Administration launched an adult smoking stop education campaign geared toward encouraging butt smokers to quit smoking.
Other factors which will facilitate the market growth throughout the forecast amount, embody the introduction of recent product and reimbursement for smoking stop medical aid.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Type, Application, and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Pfizer Inc.,GlaxoSmithKline PLC, Amgen Inc., Sanofi,Mylan N.V., F.Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., Bayer AG, Merck & Co., Inc., Novartis AG. |
The covid-19 Impact on Smoking Cessation Aids Market:
Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
Smoking Cessation Aids market Segment Overview
By Type,E-cigarettes are considered as a healthy different to tobacco cigarettes and is estimated to be the fastest growing section over the forecast amount. E-cigarettes area unit an efficient different for reducing health conditions related to tobacco, whereas vasoconstrictor replacement therapies work best for smoking cessation. E-cigarettes are a possible threat to tobacco-based cigarettes.
By Application , hospital pharmacies is increasing across the world, owing to development in infrastructural and facilities.
Market Analysis, Insights and Forecast – By Type
· Nicotine Replacement Therapy
· NRT Gum
· NRT Lozenges
· NRT Inhalers
· NRT Patches
· Sprays
· Drugs
· Electronic Cigarettes
· Others
Market Analysis, Insights and Forecast – By Application
· Hospital Pharmacies
· Online Channel
· Retail Pharmacies
· Others
Smoking Cessation Aids Market Regional Overview
Region-wise, in terms of regions ,Asia-Pacific is predicted to be the fastest growing region for the market, because of increasing awareness about the smoking cessation and plant toxin de-addiction product, and a huge population base within the area.
Smoking Cessation Aids Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Smoking Cessation Aids Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Smoking Cessation Aids are highlighted below.
· In 2020, Dr. Reddy's Laboratories launched otc nicotine Polacrilex Lozenges within the u. s.. The nicotine lozenges wholes and store brand markets witnessed u. s. retail sales of concerning USD two hundred million in 2020. the product could be a vital addition to the company’s giving of nicotine Replacement therapy.
Smoking Cessation Aids Market, Key Players -
· NJOY
· Pfizer Inc.
· GlaxoSmithKline Plc
· F. Hoffmann-La Roche AG
· Novartis AG
· Johnson and Johnson
· Bayer AG
· Cipla Ltd
· Takeda Pharmaceutical Co. Ltd.
· Dr. Reddy’s Laboratories
Frequently Asked Questions (FAQ) :
Q1. What is the total CAGR expected to be recorded for the Smoking Cessation Aids Market during the forecast period?
Q2. Which segment is projected to hold the largest share in the Smoking Cessation Aids Market?
Q3. What are the driving factors for the Smoking Cessation Aids Market?
Q4. Which Segments are covered in the Smoking Cessation Aids Market report?
Q5. Which are the prominent players offering Smoking Cessation Aids Market?
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Smoking Cessation Aids Market analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type
- 5.2.1. •Nicotine Replacement Therapy
- 5.2.2. •NRT Gum
- 5.2.3. •NRT Lozenges
- 5.2.4. •NRT Inhalers
- 5.2.5. •NRT Patches
- 5.2.6. •Sprays
- 5.2.7. •Drugs
- 5.2.8. •Electronic Cigarettes
- 5.2.9. •Others
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. •Hospital Pharmacies
- 5.3.2. •Online Channel
- 5.3.3. •Retail Pharmacies
- 5.3.4. •Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East, and Africa
6. North America Smoking Cessation Aids Market Analysis(USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Type
- 6.2.1. •Nicotine Replacement Therapy
- 6.2.2. •NRT Gum
- 6.2.3. •NRT Lozenges
- 6.2.4. •NRT Inhalers
- 6.2.5. •NRT Patches
- 6.2.6. •Sprays
- 6.2.7. •Drugs
- 6.2.8. •Electronic Cigarettes
- 6.2.9. •Others
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. •Hospital Pharmacies
- 6.3.2. •Online Channel
- 6.3.3. •Retail Pharmacies
- 6.3.4. •Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. UK
- 6.4.2. Germany
- 6.4.3. France
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Rest of Europe
7. Asia Pacific Smoking Cessation Aids Market Analysis(USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Type
- 7.2.1. •Nicotine Replacement Therapy
- 7.2.2. •NRT Gum
- 7.2.3. •NRT Lozenges
- 7.2.4. •NRT Inhalers
- 7.2.5. •NRT Patches
- 7.2.6. •Sprays
- 7.2.7. •Drugs
- 7.2.8. •Electronic Cigarettes
- 7.2.9. •Others
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. •Hospital Pharmacies
- 7.3.2. •Online Channel
- 7.3.3. •Retail Pharmacies
- 7.3.4. •Others
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. China
- 7.4.2. India
- 7.4.3. Japan
- 7.4.4. Australia
- 7.4.5. South East Asia
- 7.4.6. Rest of Asia Pacific
8. Latin America, Middle East, and Africa Smoking Cessation Aids Market Analysis(USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Type
- 8.2.1. •Nicotine Replacement Therapy
- 8.2.2. •NRT Gum
- 8.2.3. •NRT Lozenges
- 8.2.4. •NRT Inhalers
- 8.2.5. •NRT Patches
- 8.2.6. •Sprays
- 8.2.7. •Drugs
- 8.2.8. •Electronic Cigarettes
- 8.2.9. •Others
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. •Hospital Pharmacies
- 8.3.2. •Online Channel
- 8.3.3. •Retail Pharmacies
- 8.3.4. •Others
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. Brazil
- 8.4.2. Saudi Arabia
- 8.4.3. UAE
- 8.4.4. Rest of LAMEA
9. Competitive Analysis
- 9.1. Company Market Share Analysis, 2018
- 9.2. Key Industry Developments
- 9.3. Company Profile
- 9.4. • NJOY
- 9.4.1. Business Overview
- 9.4.2. Segment 1 & Service Offering
- 9.4.3. Overall Revenue
- 9.4.4. Geographic Presence
- 9.4.5. Recent Development
- 9.5. Pfizer Inc.
- 9.6. GlaxoSmithKline Plc
- 9.7. F. Hoffmann-La Roche AG
- 9.8. Novartis AG
- 9.9. Johnson and Johnson
- 9.10. Bayer AG
- 9.11. Cipla Ltd
- 9.12. Takeda Pharmaceutical Co. Ltd.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
